Monopar Therapeutics Inc. Commitments and Contingencies
Monopar Therapeutics Inc. (MNPR) had Commitments and Contingencies of $0 as of 2021-09-30, per its 10-Q filed 2021-11-12.
Discontinued › Balance Sheet › Liabilities
us-gaap:CommitmentsAndContingencies · last filed 2021-11-12
- 2021-09-30: Commitments and Contingencies $0.00.
- 2020-12-31: Commitments and Contingencies $0.00.
| Period end | Commitments and Contingencies |
|---|---|
| 2021-09-30 | $0.00 10-Q · filed 2021-11-12 |
| 2020-12-31 | $0.00 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |